Table 4.
Potential clinical factors predictive of reproductive organ involvement in previous studies
| Study | No. of pts | No. of ROI | Histology | Variables | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Palpable mass | Clinical T stage | Preoperative hydronephrosis | Clinical LNP | Neoadjuvant chemotherapy | CIS in TURT | Max tumor size in TURT | Bladder neck or trigone location | Lymphovascular invasion in TURT | ||||
| Chen 11 1997 | 115 | 6 (5.2%) | UC | NR | NR | NR | NR | NR | NR | NR | Risk factors for urethral involvement | NR |
| Varkarakis 18 2007 | 52 | 3 (5.7%) | UC | - | - | NR | - | NR | NR | NR | - | NR |
| Djaladat 10 2012 | 411 | 21 (7.5%) | UC | + | - | + | NR | - | NR | NR | NR | NR |
| Gregg 16 2016 | 160 | 32 (20%) | UC | + | NR | NR | - | NR | NR | NR | + | NR |
| Choi 15 2017 | 112 | 11 (9.8%) | UC | NR | - | + | - | NR | NR | NR | + | NR |
| Whittum 13 2018 | 118 | 17 (14%) | UC+ | NR | NR | NR | NR | - | NR | NR | + | + |
| non-UC | ||||||||||||
| Taylor 7 2019 | 123 | 19 (15%) | UC+ | NR | NR | NR | NR | - | NR | NR | NR | NR |
| non-UC | ||||||||||||
| Bree 12 2021 | 186 | 9 (4.8%) | UC | - | - | - | NR | Despite advanced stages in the neoadjuvant group, the rate of ROI was not different between the two groups. | NR | NR | NR | NR |
| Avulova 14 2023 | 1335 | 70 (5.2%) | UC+ | NR | NR | + | NR | NR | NR | NR | + | NR |
| non-UC | ||||||||||||
ROI: Reproductive organ involvement; CIS: Carcinoma in Situ; NR: Not reviewed; UC: Urothelial carcinoma, TURT: Trans-urethral resection of tumor; LNP: Lymph-adenopathy; Pts: Patients;
+
: Positive correlation;
-
: No correlation